Contribute Try STAT+ Today

OJan. 25, 2020, as the city of Wuhan headed into the world’s first Covid-19 lockdown, the Chinese billionaire Wang Jian arrived on one of the last incoming trains. Flanked by a small entourage of younger scientists, Wang exited the station wearing a mask, a light puffy jacket, and a backpack. Thousands were fleeing the river port metropolis. But Wang came ready to work.

During the SARS epidemic in 2003, the now 66-year-old geneticist had been similarly proactive, repeatedly flying to the outbreak’s epicenter in Guangdong Province to petition authorities to allow his young bioscience firm, the Beijing Genomics Institute (BGI), to sequence the deadly respiratory virus’s genome. Wang’s requests were denied until the last moment, after SARS reached Canada and scientists there became the first to sequence it — a national embarrassment for a rising China. BGI eventually sequenced the SARS genome, but the bureaucratic delay angered Wang, who built his career in the fast-moving biotech industry off ambitious, risky plays.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.